Literature DB >> 7994796

Advanced bladder cancer: options of therapy.

J E Pontes1.   

Abstract

Entities:  

Mesh：

Year:  1994        PMID： 7994796     DOI： 10.1007/BF00686929

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


× No keyword cloud information.
  21 in total

Review 1.  Neoadjuvant chemotherapy in invasive bladder cancer: the evolving role of surgery.

Authors:  H W Herr; W F Whitmore; M J Morse; P C Sogani; P Russo; W R Fair
Journal:  J Urol       Date:  1990-11       Impact factor: 7.450

2.  The surgical management of bladder carcinoma.

Authors:  G R Prout
Journal:  Urol Clin North Am       Date:  1976-02       Impact factor: 2.241

3.  Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion.

Authors:  H I Scher; A Yagoda; H W Herr; C N Sternberg; G Bosl; M J Morse; P C Sogani; R C Watson; D D Dershaw; V Reuter
Journal:  J Urol       Date:  1988-03       Impact factor: 7.450

4.  The heterogeneity of invasive bladder carcinoma and different responses to treatment.

Authors:  N H Slack; G R Prout
Journal:  J Urol       Date:  1980-05       Impact factor: 7.450

5.  Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study.

Authors:  M Stöckle; W Meyenburg; S Wellek; G Voges; U Gertenbach; J W Thüroff; C Huber; R Hohenfellner
Journal:  J Urol       Date:  1992-08       Impact factor: 7.450

6.  Systemic preoperative chemotherapy with cisplatin, methotrexate and vinblastine for locally advanced bladder cancer: local tumor response and early followup results.

Authors:  M Maffezzini; T Torelli; E Villa; P Corrada; A Bolognesi; G L Leidi; P Rigatti; B Campo
Journal:  J Urol       Date:  1991-04       Impact factor: 7.450

7.  Preliminary results in invasive bladder cancer with transurethral resection, neoadjuvant chemotherapy and combined pelvic irradiation plus cisplatin chemotherapy.

Authors:  G R Prout; W U Shipley; D S Kaufman; N M Heney; P P Griffin; A F Althausen; B Bassil; B N Nocks; E C Parkhurst; H H Young
Journal:  J Urol       Date:  1990-11       Impact factor: 7.450

8.  Selection of the type of urinary diversion in conjunction with radical cystectomy.

Authors:  J E Montie; J E Pontes; E M Smyth
Journal:  J Urol       Date:  1987-06       Impact factor: 7.450

9.  Neoadjuvant therapy in invasive bladder cancer. Problems and pitfalls.

Authors:  W R Fair
Journal:  Urol Clin North Am       Date:  1991-08       Impact factor: 2.241

10.  The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial.

Authors:  D G Skinner; J R Daniels; C A Russell; G Lieskovsky; S D Boyd; P Nichols; W Kern; J Sakamoto; M Krailo; S Groshen
Journal:  J Urol       Date:  1991-03       Impact factor: 7.450
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.